Clinical Trials Logo

Clinical Trial Summary

Hospital-acquired infections are common and frequently lead to poor outcomes, including death, in affected patients. Two common organisms that cause infections in the hospital are methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). One strategy used to prevent these infections is contact isolation of hospitalized patients with MRSA and/or VRE. It is unclear whether contact isolation decreases the rate of infection with MRSA and/or VRE. The CONTACT-PILOT study is designed to test the hypothesis that contact isolation decreases the rate of infection with MRSA and/or VRE in patients in the intensive care unit (ICU). The study will enroll all adults in the Medical ICU and will run between September 2017 and April 2018. During some months, all patients in the Medical ICU patients will be placed in isolation for MRSA or VRE if they have a current infection or colonization with either organism, or a recent history thereof. During other months, patients will only be placed in isolation for MRSA or VRE if they have an active, highly-transmissible infection with either organism, such as a pneumonia or an open, draining wound.


Clinical Trial Description

CONTACT-PILOT is a single center, pilot, multiple crossover, cluster-randomized trial of contact isolation for MRSA and VRE in the Vanderbilt Medical Intensive Care Unit (MICU) in order to determine if contact isolation reduces the rate of ICU-acquired infection with MRSA and/or VRE. Specifically, the study will randomly assign the entire MICU to one of two contact isolation strategies for 2 months, and then switch the entire MICU over to the second strategy. The first strategy is the current practice, also referred to as standard contact isolation, which is to place all patients with MRSA and/or VRE infection or colonization (or a history of either) on contact isolation. The second strategy is targeted contact isolation, in which patients with MRSA and/or VRE would only be placed on contact isolation if they have an active infection with one (or both) of these organisms with a high risk of transmission, such as an open, draining wound or a pneumonia. The study will be divided into four alternating 2-month treatment blocks, two for each strategy, with one "run-in" week at the start of each treatment block in order to transition between the two treatment strategies, for a total study duration of 8 months. The interventions will occur between September 1, 2017 and April 30, 2018. All adult MICU patients will be enrolled in the study. The primary outcome will be the rate of new ICU-acquired MRSA and VRE infections. Data analysis will be performed using a pre-specified data analysis plan. This study is being performed as a preliminary study to evaluate the feasibility and safety of the study plan. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03268122
Study type Interventional
Source Vanderbilt University Medical Center
Contact
Status Completed
Phase N/A
Start date September 1, 2017
Completion date May 30, 2018

See also
  Status Clinical Trial Phase
Completed NCT03181932 - AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis Phase 3
Completed NCT04312776 - Tracing MRSA in Households With Patients Infected With CA-MRSA by WGS
Recruiting NCT04104178 - Optimal Treatment of MRSA Throat Carriers Phase 3
Recruiting NCT04793152 - Vancomycin Dosing for Serious MRSA Infections: A Non-inferiority Randomized Trial of Trough Level Versus AUC/MIC N/A
Completed NCT03601741 - Use of Disposable Stethoscope Covers for Reduction of Stethoscope MRSA Contamination N/A
Completed NCT02690415 - Community-Assoc. S. Aureus Colonization and Recurrent Infection in Pts With Uncomplicated S. Aureus Skin Abscesses
Enrolling by invitation NCT04297592 - Antibiotic Prophylaxis in High-Risk Arthroplasty Patients Phase 4
Recruiting NCT05268120 - MRSA Decolonization in Complicated Carriage N/A
Completed NCT01167452 - Effect of Weight and/or Obesity on Sulfamethoxazole and Trimethoprim Concentrations Phase 4
Recruiting NCT04083092 - Surveillance of Community-Associated MRSA
Recruiting NCT02443064 - Pharmacokinetics/ Pharmacodynamics (PK/PD) Study of Vancomycin Phase 4
Completed NCT02029872 - Stop Community MRSA Colonization Among Patients Phase 4
Not yet recruiting NCT05696132 - Evaluation of the Decolonization Rate and Acceptance of a Complete Nasal Decolonization Kit With Povidone Iodine for MRSA Patients Phase 2
Recruiting NCT02127658 - MRSA Eradication and Decolonization in Children N/A
Completed NCT00822276 - The Underlying Mechanisms For S. Aureus Infection And Colonization Of Skin in People With Atopic Dermatitis With And Without Eczema Herpeticum (MRSA) N/A
Withdrawn NCT02547116 - Epidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic Fibrosis Phase 4
Completed NCT01318213 - Benefits of Universal Glove and Gowning
Completed NCT03304873 - Retapamulin as a Decolonizing Agent for MRSA Phase 3
Enrolling by invitation NCT05395520 - Vancomycin Monitoring: Is AUC Monitoring Appropriate for More Than Just Serious MRSA Infections?